, (GLOBE NEWSWIRE) -- (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will present at the 34 Annual .

Presentation details are as follows:

Date:
Time:
Location: Elizabethan Room B, ,
Live webcast: http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=20196

The webcast and replay of the presentation will also be accessible under the 'Investors/Events' section of the website at novavax.com.

About

(Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about is available on the Company's website, novavax.com.

Contact:

SVP, Chief Financial Officer and Treasurer

, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com
240-268-2000

, Ph.D.

david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271



Novavax Inc. issued this content on 2016-01-06 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-06 21:10:07 UTC

Original Document: http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=2126968